Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RRx-001 |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
RRx-001 is a nitric oxide donor that is activated by hypoxia, leading to increased oxygen level in tumor and sensitizes tumor to radiotherapy (PMID: 26164533, PMID: 32169409). |
| DrugClasses | |
| CAS Registry Number | 925206-65-1 |
| NCIT ID | C97130 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + Etoposide + RRx-001 | Carboplatin Etoposide RRx-001 | 0 | 1 |
| Cisplatin + Etoposide + RRx-001 | Cisplatin Etoposide RRx-001 | 0 | 1 |
| Cisplatin + RRx-001 | Cisplatin RRx-001 | 0 | 1 |
| Irinotecan + RRx-001 | Irinotecan RRx-001 | 0 | 1 |
| Irinotecan + RRx-001 + Temozolomide | Irinotecan RRx-001 Temozolomide | 0 | 1 |
| Radiotherapy + RRx-001 + Temozolomide | RRx-001 Radiotherapy Temozolomide | 0 | 0 |
| RRx-001 | RRx-001 | 0 | 4 |
| RRx-001 + Temozolomide | RRx-001 Temozolomide | 0 | 1 |